Cel­gene scores an­oth­er win for megablock­buster con­tender ozan­i­mod, but it's haunt­ed by key dis­abil­i­ty miss

Cel­gene post­ed an­oth­er key Phase III suc­cess for its megablock­buster con­tender ozan­i­mod, once again un­der­scor­ing its po­ten­tial to dis­rupt the mul­ti­ple scle­ro­sis field.

In­ves­ti­ga­tors held …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER